Corrigendum

Abstract

This is a corrigenda regarding the article published in J Obstet Gynaecol Res 2007;33(2):166–173. In this article, blood levels of Prostate Specific Antigen (PSA) were mentioned to be determined by a commercial assay (Immulite 2000 Analyser Diagnostic Products, Los Angeles, CA, USA) with an analytical sensitivity of 0.04 ng/mL (0.04–150 ng/mL). However, PSA levels in Polycystic Ovary Syndrome and control subjects were found to be 0.026 ± 0.023 ng/mL and 0.009 ± 0.008 ng/mL respectively which seem to be impossible to be detected with the aforementioned commercial assay. It has been verified that Ultrasensitive Third Generation PSA Assays had been used in this study which offer an additional 10-fold improvement in low-end analytical sensitivity, with a claimed detection limit of 0.003 ng/mL 1. Unfortunately, the low-end analytical sensitivity of Second Generation PSA Assay (0.04 ng/mL) was written instead of the low-end analytical sensitivity of Third Generation PSA Assay (0.003 ng/mL) in the ‘Material and Methods’ section. The literature data are attached 1. We apologize for the inconvenience.